

FOR IMMEDIATE RELEASE

Bioniche Life Sciences signs agreement with Cumberland Pharmaceuticals Inc.

-Companies establish exclusive manufacturing arrangements-

BELLEVILLE, ONTARIO & NASHVILLE, TN, February 26, 2002 – Bioniche Life Sciences Inc., (BNC: TSE), a fully integrated Canadian biopharmaceutical company serving both the human and animal health markets, today announced that the Company's specialty pharmaceutical division, Bioniche Pharma, has signed an exclusive manufacturing and supply agreement with Cumberland Pharmaceuticals Inc., a U.S. pharmaceutical company based in Tennessee.

“This collaboration with Cumberland is an important development for our pharmaceutical division,” said Albert Beraldo, President of Bioniche Pharma. “Joint ventures for the development and production of specialty pharmaceuticals with companies like Cumberland Pharmaceuticals are an integral part of our strategic plan to become a key player in the sterile injectable market in the U.S.”

This agreement with Cumberland is for the manufacture and supply of N-Acetylcysteine on an exclusive basis for a five-year period, at agreed upon terms. N-Acetylcysteine is a mucolytic agent that Bioniche currently supplies to the Canadian market under the Parvolex® brand name and will supply to Cumberland for the U.S. market under Cumberland's brand name, Acetadote™. The agreement also includes a strategic alliance with Cumberland to explore other initiatives in the U.S. and Canadian sterile injectable markets.

“We are delighted with this new relationship with Bioniche,” said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. “Combining Bioniche's manufacturing capability with our U.S. sales and marketing capabilities will speed the introduction of our branded N-acetylcysteine product into the U.S. We also believe that there is an excellent match between the strategies of our companies, which should lead to ongoing opportunities to work together.”

About Cumberland Pharmaceuticals:

Cumberland Pharmaceuticals Inc. is a Tennessee-based company formed to acquire and market a portfolio of niche pharmaceutical products to specific physician segments such as critical care, gastroenterology, pulmonology and emergency medicine. The Company's focus is on acquiring rights to existing products and concentrating on under-served healthcare segments. The company recently launched the promotion Kristalose®, a gastroenterology product throughout the U.S., based on an agreement with Mylan Laboratories' Bertek Pharmaceuticals. For more information, visit www.cumberlandpharma.com

About Bioniche Pharma:

The Bioniche Life Sciences pharmaceutical division has a range of over 35 specialty sterile injectable products and has an aggressive product development program aimed at the registration of over 10 new products over the next few years. The division experienced a 30% increase in sales in fiscal 2001 and is expected to achieve a 40% increase this fiscal year. Bioniche is a leading Canadian biopharmaceutical company that develops, manufactures and markets proprietary products for human and animal markets worldwide. For more information visit www.bioniche.com